- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Medicenna Therapeutics Corp: Medicenna Therapeutics has change in transfer agent | 1 | Stockwatch | ||
| 28.06. | Medicenna Therapeutics Corp: Medicenna's March 31 cash position at $17-million | 2 | Stockwatch | ||
| 27.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights | 110 | GlobeNewswire (Europe) | Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity... ► Artikel lesen | |
| 26.06. | Medicenna Therapeutics Corp: Medicenna receives EMA approval for Ability-1 trial | 1 | Stockwatch | ||
| 26.06. | Medicenna Therapeutics Corp.: Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe | 371 | GlobeNewswire (Europe) | - ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®... ► Artikel lesen | |
| 03.06. | RBC, Kits, Medicenna at 52-Week Highs on News | 1 | Baystreet.ca | ||
| 03.06. | Medicenna Therapeutics Corp: Medicenna presents phase 2b bizaxofusp results at ASCO | 1 | Stockwatch | ||
| 03.06. | Medicenna reveals positive results from brain cancer study | 2 | The Market Herald Canada | ||
| 03.06. | Medicenna Therapeutics Corp.: Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting | 66 | GlobeNewswire (Europe) | Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval:... ► Artikel lesen | |
| 31.05. | Medicenna Therapeutics Corp.: Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation ... | 1 | GlobeNewswire (USA) | ||
| 22.05. | Medicenna Therapeutics Corp.: Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum | 1 | GlobeNewswire (USA) | ||
| 14.05. | Medicenna Therapeutics Corp. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
| 13.05. | Medicenna Therapeutics Corp. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.05. | Medicenna Therapeutics Corp: Medicenna denies breaking ASCO prior-publication policy | 1 | Stockwatch | ||
| 13.05. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 13.05. | Medicenna Therapeutics Corp.: Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 30.04. | Medicenna Therapeutics Corp: Medicenna closes $20M investment from RA Capital | 1 | Stockwatch | ||
| 30.04. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management | 1 | GlobeNewswire (USA) | ||
| 26.04. | Medicenna Therapeutics Corp: Medicenna arranges $20M private placement | 1 | Stockwatch | ||
| 26.04. | Medicenna Therapeutics Corp: Medicenna Therapeutics resuming at the open | 1 | Stockwatch |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,556 | +2,96 % | EQS-News: Defence Therapeutics Inc.: Defence Therapeutics erhält Unterstützung durch das CNRI-H-Projekt von Canadian Nuclear Laboratories zur Beschleunigung der Entwicklung seines Radioimmunokonjugat-Programms | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,316 | -7,60 % | Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? | ||
| BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
| ONCOLYTICS BIOTECH | 0,935 | 0,00 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights | Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET
SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
| ASSERTIO | 1,505 | +2,38 % | Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024 | ||
| ARCTURUS THERAPEUTICS | 24,030 | +4,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs | ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,700 | +0,38 % | Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark | ||
| SIGA TECHNOLOGIES | 10,520 | +5,09 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,160 | +0,61 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 7,400 | -1,07 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,980 | -1,88 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy positioned to be the first and only needle-free adrenaline option authorized for emergency treatment of allergic reactions (anaphylaxis) in Europe Positive CHMP opinion and recommendation... ► Artikel lesen | |
| ARVINAS | 29,650 | +0,44 % | Arvinas Inc.: Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer | - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology... ► Artikel lesen |
Das Unternehmen MEDICENNA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,004 (+2,55 %) liegt der Kurs bei 0,161 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.
